KOD

Kodiak Sciences Inc

Add to Watchlist

Advanced Chart

20.770

+1.18(6.023%)1D

Line

Candle

YTD

High

21.9453

Open

19.460

VWAP

20.88

Vol

987.72K

Mkt Cap

1.10B

Low

19.250

Amount

20.62M

EV/EBITDA(TTM)

Total Shares

52.53M

1.03B

EV/OCF(TTM)

P/S(TTM)

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

-0.650

-36.89%

-0.630

-42.2%

-1.062

+26.45%

Estimates Revision

The market is revising No Change the revenue expectations for Kodiak Sciences Inc. (KOD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 103.63%.

EPS Estimates for FY2025

Revise Upward

+3.72%

In Past 3 Month

Stock Price

Go Up

+103.63%

In Past 3 Month

6 Analyst Rating

13.14% Upside

Wall Street analysts forecast KOD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 23.50 USD with a low forecast of 14.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

13.14% Upside

Current: 20.770

Low

14.00

Averages

23.50

High

40.00

13.14% Upside

Current: 20.770

Low

14.00

Averages

23.50

High

40.00

H.C. Wainwright

Matthew Caufield

Buy

maintain

$24 -> $26

2025-11-17

New

Reason

H.C. Wainwright

Matthew Caufield

Price Target

$24 -> $26

2025-11-17

New

maintain

Buy

Reason

H.C. Wainwright analyst Matthew Caufield raised the firm's price target on Kodiak Sciences to $26 from $24 and keeps a Buy rating on the shares. The firm sees a near-term catalyst for shares from the Phase 3 GLOW2 trial in reformulated tarcocimab in diabetic retinopathy patients expected Q1.

H.C. Wainwright

Matthew Caufield

Neutral -> Buy

upgrade

$5 -> $24

2025-11-11

Reason

H.C. Wainwright

Matthew Caufield

Price Target

$5 -> $24

2025-11-11

upgrade

Neutral -> Buy

Reason

H.C. Wainwright analyst Matthew Caufield upgraded Kodiak Sciences to Buy from Neutral with a price target of $24, up from $5, after the company reported follow-up data from the Phase 1b APEX trial of KSI-101 in patients with macular edema secondary to inflammation. The data support continued best corrected visual acuity improvement and sustained retinal dryness, the analyst tells investors in a research note. H.C. Wainwright says its retinal work supports the prospects for KSI-101, and broader tarcocimab and KSI-501 retinal development.

JPMorgan

Neutral -> Overweight

upgrade

$15 -> $24

2025-10-24

Reason

JPMorgan

Price Target

$15 -> $24

2025-10-24

upgrade

Neutral -> Overweight

Reason

JPMorgan upgraded Kodiak Sciences to Overweight from Neutral with a price target of $24, up from $15. The firm believes the company's KSI-101 in macular edema secondary to inflammation is "de-risked" and could drive upside in the shares as the opportunity is better appreciated by the market. Data from the Phase 3 PEAK and PINNACLE studies of KSI-101 are anticipated in Q4 of 2026 and Q1 of 2027, respectively, the analyst tells investors in a research note.

LifeSci Capital

NULL

Outperform

initiated

$40

2025-10-23

Reason

LifeSci Capital

Price Target

$40

2025-10-23

initiated

NULL

Outperform

Reason

LifeSci Capital initiated coverage of Kodiak Sciences with an Outperform rating and $40 price target.

Barclays

Gena Wang

Underweight -> Equal Weight

upgrade

$7 -> $17

2025-09-25

Reason

Barclays

Gena Wang

Price Target

$7 -> $17

2025-09-25

upgrade

Underweight -> Equal Weight

Reason

Barclays analyst Gena Wang upgraded Kodiak Sciences to Equal Weight from Underweight with a price target of $17, up from $7. The firm says Roche's Phase 2 vamikibart plus ranibizumab data in diabetic macular edema provide "important clinical validation" Kodiak's for KSI-101. The clinical profiles are largely comparable and key opinion leader feedback suggest a low bar for practice adoption with KSI-101, the analyst tells investors in a research note.

Jefferies

initiated

$15

2025-09-22

Reason

Jefferies

Price Target

$15

2025-09-22

initiated

Reason

Jefferies initiated coverage of Kodiak Sciences (KOD) with a Buy rating and $15 price target. Kodiak has three drugs in Phase 3 study for eye diseases, each with key readouts in 2026, including lead asset '101 with data expected in Q4 of 2026 to Q1 of 2027, the analyst tells investors. A nearer-term catalyst may come from competitor Roche's (RHHBY) data expected soon at the AAO meeting, the analyst added.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kodiak Sciences Inc (KOD.O) is -6.56, compared to its 5-year average forward P/E of -6.46. For a more detailed relative valuation and DCF analysis to assess Kodiak Sciences Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.46

Current PE

-6.56

Overvalued PE

3.19

Undervalued PE

-16.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

5.32

Undervalued EV/EBITDA

-15.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.93

Current PS

0.00

Overvalued PS

5.50

Undervalued PS

-3.64